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Embryonic stem cells (ESCs) are an attractive
source for tissue regeneration and repair therapies
because they can be differentiated into virtually
any cell type in the adult body. However, for this
approach to succeed, the transplanted ESCs must
survive long enough to generate a therapeutic
benefit. A major obstacle facing the engraftment
of ESCs is transplant rejection by the immune
system. Here we show that blocking leukocyte
costimulatory molecules permits ESC engraftment.
We demonstrate the success of this immunosup-
pressive therapy for mouse ESCs, human ESCs,
mouse induced pluripotent stem cells (iPSCs),
human induced pluripotent stem cells, and more
differentiated ESC/(iPSCs) derivatives. Additionally,
we provide evidence describing the mechanism
by which inhibition of costimulatory molecules
suppresses T cell activation. This report describes
a short-term immunosuppressive approach capa-
ble of inducing engraftment of transplanted ESCs
and iPSCs, providing a significant improvement in
our mechanistic understanding of the critical
role costimulatory molecules play in leukocyte acti-
vation.
INTRODUCTION
In recent years, there has been much interest in using human
embryonic stem cells (hESCs) to regenerate tissues and
organs. However, despite the potential of hESCs, important
issues surrounding immunogenicity have not been fully ad-
dressed, and strategies to avoid rejection remain largely
untested. Previous studies have demonstrated that traditional
immunosuppressive therapies (e.g., tacrolimus, sirolimus, and
mycophenolate mofetil) provide only marginal improvementsin embryonic stem cells (ESC) survival, with little evidence
of cell engraftment past 3–4 weeks after transplantation (Swij-
nenburg et al., 2008; Toriumi et al., 2009). Furthermore, tradi-
tional immunosuppression requires chronic administration,
leaving the host immune system impaired and vulnerable to
opportunistic infections. Thus, the ideal therapy should involve
only a brief period of immunosuppression but be able to
induce a specific long-lasting tolerance to the donor cells
(Chidgey et al., 2008). With this goal in mind, we tested
whether a brief course of treatment with three costimulatory
receptor-blocking agents—cytotoxic T-lymphocyte-associated
antigen 4 (CTLA4)-Ig, anti-CD40 ligand (anti-CD40L), and anti-
lymphocyte function-associated antigen 1 (anti-LFA-1)—could
induce long-term allogeneic and xenogeneic ESC engraftment.
We investigated these agents because blocking various
combinations of these costimulatory molecules has demon-
strated promise for hESCs in the immune-privileged environ-
ment of the testis (Grinnemo et al., 2008) and has been
demonstrated to prolong the survival of cardiac allografts
(Larsen et al., 1996), pancreatic islet cells (Lenschow et al.,
1992), and bone marrow grafts (Kurtz et al., 2009; Pan et al.,
2003).
An optimal T cell response requires two signals, ligation of the
antigen-specific T cell receptor (TCR) (signal 1) and an accessory
signal from a non-antigen-specific costimulatory molecule
(signal 2) (Jenkins, 1994). When only signal 1 is provided without
signal 2, T cell activation is disturbed, and the cell may adopt
a state of anergy or undergo apoptosis, abortive proliferation,
or immunoregulation (Ford and Larsen, 2009; Wood and
Sakaguchi, 2003). Among the most important costimulatory
interactions for T cell activation are the interaction between
CD80/CD86 on antigen presenting cells (APC) and CD28 on
T cells and the engagement between CD40 on APCs and
CD40 ligand on T cells (Lafferty et al., 1983). Negatively regu-
lating costimulatory molecules have also been described,
particularly CTLA4, which is expressed by activated T cells
and binds to CD80/CD86 with 10- to 20-fold greater affinity
than CD28 (Thompson and Allison, 1997). Upon engagement,
CTLA4 delivers an inhibitory signal to the T cell. Lastly, LFA-1
is involved in the formation of the immunological synapse asCell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc. 309
Cell Stem Cell
Tolerance to ESCs and iPSCs by Costimulatory Blockadewell as the trafficking and costimulation of T cells (Van Seventer
et al., 1990; Zuckerman et al., 1998).
RESULTS
Blockade of Leukocyte Costimulatory Molecules
Permits Long-Term Engraftment of Mouse ESCs
Transplanted across Allogeneic Barriers
Finding or creating the right techniques to evaluate transplanted
cell survival is essential for the accurate assessment of immuno-
logic rejection and drug discovery (Niu and Chen, 2008).
Until recently, the majority of studies evaluating ESC survival
depended on immunohistochemical staining for b-galactosidase
(LacZ) (Caspi et al., 2007) or detection of GFP (Li et al., 2004). But
these methods only provide a snapshot of cell survival. In
contrast, in vivo bioluminescent imaging (BLI) provides longitu-
dinal evaluation of the spatiotemporal kinetics of ESC rejection.
In this study, mouse ESCs (mESCs) and hESCs were transduced
with a double fusion (DF) reporter gene construct carrying firefly
luciferase (Fluc) and enhanced green florescent protein (eGFP)
(Figure 1A). ESCs robustly expressed Fluc, which correlated
with ESC number (r2 = 0.99) and displayed a tight cluster
morphology with robust GFP expression (Figure S1A, available
online).
We next investigated longitudinal survival after intramuscular
(gastrocnemius muscle) transplantation of mESCs into synge-
neic (SV129, H-2kb) and allogeneic (BALB/c, H-2kd) mice by
in vivo BLI. mESC survival was significantly limited in allogeneic
compared to syngeneic mice (p < 0.001), with BLI signal
decreasing to background levels in allogeneic animals by
21 days after transplantation. In contrast, syngeneic hosts
accepted mESC grafts, resulting in teratoma formation (Figures
1B and 1C). Having previously demonstrated that the immune
response to hESCs is primarily CD4+ T cell-mediated, we there-
fore investigated the efficacy of immunosuppressive agents
that largely target T cells (Swijnenburg et al., 2008). Two immu-
nosuppressive agents were chosen on the basis of different
mechanisms of action, specifically calcineurin inhibitors (tacro-
limus; TAC) and target of rapamycin inhibitors (sirolimus; SIR)
(Table S1). Additionally, three costimulatory receptor-blocking
antibodies (CTLA4-Ig, anti-LFA-1, and anti-CD40L) were evalu-
ated in an attempt to induce immune tolerance. Importantly,
costimulatory blockade was only administered for a brief
interval of time spanning days 0, 2, 4, and 6 after transplanta-
tion. Whereas daily administration of TAC/SIR prolonged
mESC survival only out to 28 days after transplantation,
a surprisingly brief course of costimulatory blockade was suffi-
cient to prevent mESC rejection at all time points assayed
(p < 0.001 costimulatory blockade treatment versus TAC/SIR
or no treatment) (Figures 1B and 1C). To exclude the possibility
that the immune reaction was exclusively targeted toward anti-
gens produced by the DF reporter genes, we transplanted non-
transduced mESCs that do not express Fluc-eGFP. Similar to
mESCs expressing Fluc-eGFP, costimulatory blockade treat-
ment permitted engraftment of nontransduced mESCs. Survival
of nontransduced mESCs was limited in both untreated
and TAC/SIR-treated allogeneic hosts with no evidence of
transplanted mESC survival at 28 days after transplantation
(Figure 1D).310 Cell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc.Xenogeneic Immune Rejection of Undifferentiated,
In Vivo Differentiated, and hESC-Derived Endothelial
Cells Is Mitigated by Costimulatory Blockade
We next investigated whether costimulatory blockade could
prevent immune rejection of hESCs in the more hostile xenoge-
neic transplantation environment. Without immunosuppression,
hESC survival was significantly limited as BLI signal reached
background intensity by day 10–14, whereas BLI signal steadily
increased at each time point assayed in the costimulatory
blockade treatment group (p < 0.01, Figure 1E). Consistent
with BLI data, histological evaluation of the graft site at 5 days
following hESC transplantation demonstrated a robust infiltra-
tion of CD3 T cells surrounding GFP+ hESCs, which was severely
diminished in the costimulatory blockade-treated group (Fig-
ure S1B). At 28 days there was no histological evidence of
hESC survival in untreated animals, whereas animals treated
with costimulatory blockade demonstrated teratoma formation
(Figure 1F). Having shown that the combination of three costimu-
latory blockade agents is capable of inducing hESC engraft-
ment, we next tested whether monotherapy is sufficient. By
day 28, BLI signal decreased to background intensity in all
monotherapy groups, with the greatest prolongation of hESC
survival observed in the anti-LFA-1 group (Figure 1E).
Undifferentiated ESCs have low levels of major histocompati-
bility complex (MHC) expression (Figure S1C), which increases
upon differentiation (Figures 2A and 2B). These differentiated
ESC-derivatives may have impaired survival capacity compared
to undifferentiated ESCs when transplanted across histocom-
patibility barriers. This represents a problem, as it is unlikely
that ESC-based therapy will utilize an undifferentiated cell pop-
ulation because of safety concerns regarding potential teratoma
formation or uncontrolled cellular proliferation. It is likely that
prior to transplantation, cells will need to be differentiated into
a lineage appropriate for their intended therapy and thus may
encounter a heightened immune response. We therefore tested
the ability of costimulatory blockade to permit engraftment of (1)
an in vivo spontaneously differentiated cell population isolated
from an explanted hESC-derived teratoma and (2) in vitro differ-
entiated hESC-derived endothelial cells (hESC-ECs). Both cell
populations demonstrated increased MHC-I expression relative
to undifferentiated cells (Figures 2A and 2B). Immunosuppres-
sive treatment with costimulatory blockade permitted engraft-
ment of in vivo differentiated cells (p < 0.01 untreated versus
costimulatory blockade treated, Figure 2C and Figure S2A)
and in vitro differentiated hESC-ECs comparable to that
observed in immunodeficient nonobese diabetic/severe com-
bined immunodeficiency (NOD/SCID) mice (p < 0.05 untreated
versus costimulatory blockade treated, Figure 2D and Fig-
ure S2B). Transplantation of in vivo differentiated hESCs without
immunosuppression resulted in limited cell survival as indicated
by BLI signal diminishing to background level by 7 to 14 days. In
contrast, treatment with costimulatory blockade permitted
engraftment of in vivo differentiated hESC as indicated by
steadily increasing BLI signal at every time point assayed. Trans-
plantation of hESC-ECs demonstrated limited survival in all
groups tested, including the immunodeficient NOD/SCID mice.
At day 4 following hESC-EC transplantation, the BLI signal was
18.5% ± 6.0% of baseline in the untreated group, compared to
46.7% ± 16% in the costimulatory blockade-treated group. By
Figure 1. Blockade of Leukocyte Costimulatory Molecules Mitigates Allogeneic and Xenogeneic Transplantation Rejection of Undifferenti-
ated ESCs
(A) Schema of the DF reporter gene construct containing Fluc and eGFP driven by a constitutive human ubiquitin promoter, using a self-inactivating (SIN) lentiviral
vector.
(B) Representative bioluminescence images and (C) quantitative bioluminescence intensity of mESC-transplanted mice that received either no treatment, tacro-
limus plus sirolimus (T/S), CTLA4-Ig + anti-LFA-1 plus anti-CD40L (COSTIM), or COSTIM plus T/S. n = 5 per group, ***p < 0.001.
(D) Representative images of gastrocnemius muscles 28 days after transplantation of nontransduced mESCs.
(E) Representative bioluminescence images of xenogeneic hESC-transplanted mice that received no treatment, monotherapy, or a combination of all three
costimulatory blockade agents (COSTIM). n = 5–8 per group.
(F) Histopathological evaluation of hematoxylin and eosin-stainedmuscle sections fromCOSTIM-treated mice demonstrating hESC-derived teratoma formation.
All values are expressed as mean ± SEM. Color scale bars are in photons per second per centimeter squared per steradian (p/s/cm2/sr). For further character-
ization of the ESCs and iPSCs see Figure S1.
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untreated group compared to 7.9% ± 3.1% in the costimulatory
blockade-treated group (p < 0.05, Figure 2D and Figure S2B).
Finally, we extended our analysis of the immunosuppressive effi-
cacy of costimulatory blockade to include the transplantation of
bone marrow mononuclear stem cells (BMMCs). This cell typewas chosen because it represents a well-characterized and
potentially clinically relevant stem cell population (Assmus et al.,
2006). Mouse BMMCs were rejected by untreated allogeneic
recipientsby10days following transplantation,whereascostimu-
latory blockade-treated mice demonstrated persistent BLI signal
at 100 days following transplantation (p < 0.01, Figure S2C).Cell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc. 311
Figure 2. Leukocyte Costimulatory Molecule Blockade Permits Engraftment of Differentiated hESC-Derivatives
Mean fluorescence intensity of MHC antigens, pluripotency (SSEA-4), and endothelial (CD31) markers on (A) in vivo differentiated hESCs isolated from explanted
teratoma and (B) in vitro differentiated hESC-ECs. Filled histograms represent isotype control antibodies.
(C) BLI of the survival of in vivo differentiated hESCs transplanted into immunodeficient (NOD/SCID) and immunocompetent (BALB/c) mice that received either
costimulatory blockade (COSTIM) or no immunosuppressive treatment, n = 3–4 per group.
(D) Bioluminescence photon intensities representing the survival of in vitro differentiated hESC-ECs after transplantation into immunodeficient, costimulatory
blockade (COSTIM)-treated, or nontreated immunocompetent (BALB/c) mice, n = 4 per group, *p < 0.05. All values are expressed as mean ± SEM. For additional
engraftment data regarding differentiated ESCs see Figure S2.
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Pluripotent Stem Cells Results in Immune Rejection
that Can Be Prevented by Costimulatory Blockade
For regenerative medicine purposes, an alternative source of
pluripotent cells is human induced pluripotent stem cells
(hiPSC). hiPSCs can be generated by delivering transcription
factors to reprogram somatic cells toward a state of pluripotency312 Cell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc.(Takahashi et al., 2007; Yu et al., 2007). To assess the immuno-
genic properties of hiPSCs and the efficacy of costimulatory
blockade to induce long-term engraftment of hiPSCs, we
created four hiPSC lines from human adipose stem cells
(hASC) isolated from four different patients. These hiPSC colo-
nies stained positive for the pluripotency markers alkaline phos-
phatase (AP), Nanog, SSEA-3, SSEA-4, and Oct4 (Figure 3A).
Figure 3. Leukocyte CostimulatoryMolecule Blockade Permits Xenogeneic and Allogeneic Engraftment of hiPSC,miPSC, andDifferentiated
miPSC-Derivatives
(A) Characterization of hiPSCs by immunostaining with pluripotency markers such as Nanog, Oct4, SSEA-3, SSEA-4, and alkaline phosphatase.
(B) Mean fluorescence intensity of MHC antigens and pluripotency markers on undifferentiated hiPSCs. Filled histograms represent isotype control antibodies.
BLI and bioluminescence photon intensities representing the survival of (C) hiPSCs and (D) miPSCs transplanted into the gastrocnemius muscle of immunode-
ficient (NOD/SCID) and immunocompetent mice receiving costimulatory blockade (COSTIM) or no treatment. n = 3–5 per group, *p < 0.05, **p < 0.01, ***p < 0.001.
All values are expressed as mean ± SEM.
(E) In vitro differentiated miPSC-NSCs transplanted into the subcortical area of the brain in immunodeficient (NOD/SCID) and immunocompetent mice.
n = 3–4 per group. For additional characterization and engraftment data regarding miPSCs and hiPSCs, see Figure S3 and Movie S1.
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similar surface expression levels of pluripotencymarker SSEA-4,
lack of MHC-II, and slightly higher levels of MHC-I (Figure 3B).
We performed microarray gene expression analyses that
demonstrated that the four hiPSC lines are similar to H7 hESCs
(Wicell) and distinct from hASCs (Figures S3A). The pluripotency
of hiPSCs was examined through the formation of embryoid
bodies (EBs). hiPSC-EBs expressed multiple markers corre-
sponding to each of the three embryonic germ layers (Fig-
ure S3B). The hiPSC-EBs demonstrated the capacity for multili-
neage differentiation as we were able to derive neurons,
endothelial cells, and beating cardiomyocytes (Figures S3B
and S3C and Movie S1). Upon transplantation into immunocom-
petent mice, hiPSC survival was significantly limited in
untreated compared with costimulatory blockade-treated mice
because the BLI signal decreased to background levels in
untreated animals by 7 days after transplantation, whereas
engraftment with steadily increasing BLI signal and teratoma
formation were observed in costimulatory blockade-treated
animals (p < 0.01, Figure 3C and Figure S3D). To assess efficacy
of costimulatory blockade in an allogeneic transplant model,
we generated mouse induced pluripotent stem cells (miPSCs)
from transgenic FVB (H-2kq) mice that constitutively express
eGFP-Fluc under an ubiquitin promoter and followed survival
in BALB/c (H-2kd) mice by in vivo BLI. In the absence of immu-
nosuppression, transplanted miPSC survival was significantly
limited to 14 to 21 days after transplantation. However, when
allogeneic mice were treated with costimulatory blockade, pro-
longed engraftment with steadily increasing BLI signal and tera-
toma formation were observed in all animals (Figure 3D and Fig-
ure S3E). Similar to ESC-based therapy, induced pluripotent
stem cells (iPSC)-based therapy will probably utilize a differenti-
ated rather than undifferentiated cell population. Hence
we generated miPSC-derived neural stem cells (miPSC-NSC)
(Figure S3C) to investigate the survival of this cell population
in untreated and costimulatory blockade-treated allogeneic
recipients. Survival of miPSC-NSCs was significantly limited in
untreated compared to costimulatory blockade-treated mice
(p < 0.01, Figure 3E). At day 14 following transplantation, the
BLI signal in the untreated group was 24.7% ± 6.8% of the
initial BLI intensity, compared to 60.9% ± 6.5% in the costimu-
latory blockade-treated group (p < 0.01). By day 21, the BLI
signal in the untreated group had diminished to background
intensity whereas the BLI signal was 51.1% ± 5.3% of the initial
BLI intensity in the costimulatory blockade-treated group
(p < 0.001).
Costimulatory Blockade Inhibits Allogeneic Leukocyte
Proliferation with Limited Systemic Toxicity
To address the mechanism by which costimulatory blockade
permits engraftment of pluripotent cells and their differentiated
derivatives, we next examined the effect of costimulatory
blockade on both the ESCs and the host. One possible mech-
anism by which the agents support engraftment is to stimulate
increased ESC proliferation. To test this hypothesis, we trans-
planted undifferentiated hESCs into immunodeficient mice
randomized to receive either costimulatory blockade or saline
as control. Between the two groups, we observed no significant
difference in the kinetics of hESC proliferation and teratoma314 Cell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc.formation (Figure 4A), suggesting these agents do not improve
survival by stimulating increased cell proliferation. We next
investigated the effect of costimulatory blockade on ESC
viability by comparing the percentage of ESCs undergoing
early versus late apoptosis. There was no significant difference
between ESCs exposed to costimulatory blockade versus
unexposed controls (Figure S2D). To evaluate the toxicity
of the costimulatory blockade agents on the host, we com-
pared hematologic, renal, hepatic, and metabolic parameters
between costimulatory blockade and untreated mice. For all
parameters assayed, costimulatory blockade mice demon-
strated similar laboratory values as untreated mice (Table S2).
The low toxicity of costimulatory blockade immunosuppres-
sion highlights another advantage of costimulatory blockade
over traditional immunosuppressive approaches (e.g., TAC
and SIR). Another advantage is that costimulatory blockade re-
quires only a short period of administration. However, if costi-
mulatory blockade diminishes the ability of the host to mount
a robust immune response to future antigens, then the potential
for clinical translation of this approach would be severely
decreased. To address the ability of costimulatory blockade-
treated hosts to reject third party antigens, we injected hESCs
into immunocompetent mice that had previously accepted
miPSC-NSC grafts. The transplanted hESCs were rejected,
indicating that despite previous costimulatory blockade treat-
ment, the mice were fully capable of rejecting third party anti-
gens (Figure S4A).
To characterize the effect of costimulatory blockade on the
host immune response, we next performed mixed lymphocyte
reactions (MLR) with MHC mismatched splenocytes as
stimulators and responders. Relative to untreated controls,
costimulatory blockade significantly mitigated both CD4+ (p <
0.0001) and CD8+ (p = 0.0002) T cell proliferation (Figure 4B).
To determine the contribution of T regulatory (Treg) cells
toward the costimulatory blockade induced survival of hESCs,
we compared the absolute number of CD4+FoxP3+ T cells in
costimulatory blockade and untreated mice 21 days after
hESC transplantation. Relative to untreated controls, costimu-
latory blockade significantly decreased the total number of
CD4+FoxP3+ T cells (p = 0.002) (Figure 4C), as well as the
percent of CD4+ T cells that were CD4+FoxP3+ cells (p = 0.006)
(Figure 4D). To assess the immunosuppressive ability of the
Treg cells that develop in costimulatory blockade-treated
mice, we performed MLRs as described above with or without
the inclusion of CD4+CD25hi T cells. The inclusion of CD4+
CD25hi T cells significantly mitigated the proliferation of CD8+
T cells (p = 0.0005) (Figure S4B). However, the CD4+CD25hi
T cells isolated from costimulatory blockade mice did not
possess a significantly different immunosuppressive potency
than CD4+CD25hi T cells isolated from untreated mice (p =
nonsignificant).
Gene Expression Characterization of Leukocytes
Treated with Costimulatory Molecule Blockade
Certain genetic regulatory programs have previously been
described for anergic (Safford et al., 2005) or for optimally acti-
vated T cells (Diehn et al., 2002). To elucidate the gene expres-
sion footprint of costimulatory blockade-treated T cells, we
performed microarray gene expression analysis comparing
Figure 4. Gene Expression and Functional
Characterization of Leukocytes Treated
with Costimulatory Molecule Blockade
(A) Bioluminescence photon intensities represent-
ing the survival of hESCs in immunodeficient
(NOD/SCID) mice treated with COSTIM or saline
as control. n = 5 per group.
(B) Mixed lymphocyte reaction comparing the
proliferation of COSTIM-treated and untreated
T cell subsets stimulated by allogeneic spleno-
cytes. *p < 0.0001, **p = 0.0002. Shown is a repre-
sentative trial chosen from three independent trials
demonstrating similar results.
(C) Comparison of the total number of CD4+
FoxP3+ T cells and (D) percent of CD4+ cells that
are FoxP3+ isolated from mice treated with
COSTIM or saline as control. n = 6 COSTIM,
n = 3 untreated control, *p = 0.006, **p = 0.002.
All values expressed in panels (A–D) represent
mean ± SEM.
(E) Hierarchical clustering of T cells stimulated
by allogeneic splenocytes reveals distinct gene
expression clusters between COSTIM-treated
and untreated T cells. Biological duplicates for
each group are shown.
(F) Gene expression fold change of COSTIM-
treated relative to untreated T cells. For additional
characterization of the costimulatory blockade-
treated responder T cells see Figure S4.
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untreated responder T cells. Relative to untreated, the costimu-
latory blockade-treated group had 96 and 40 genes significantly
(p < 0.05) down- and upregulated, respectively (Figure 4E and
Table S3). Next, we analyzed these genes in terms of their
functional relationships with Ingenuity Network software that
correlates these significantly expressed genes to the signaling
and metabolic pathways, molecular networks, and biological
processes that are most significantly affected in the costimula-
tory blockade-treated group (Table S3). The key genes impli-
cated in the establishment of costimulatory blockade induced
allograft tolerance and host anergy were identified thereafter.
Figure 4F represents the fold change of those genes, which
include Egr2, GPNMB, BCL2, IL-2, Ccl3, Lta, Stat1, Cdkn1a,
Socs2,Gzmb, and TNFRSF9. Finally, we predicted the probableCell Stem Cell 8, 309–3gene regulatory network that is respon-
sible for inhibiting T cell activation, prolif-
eration, and survival in the costimulatory
blockade-treated group (Figure S4C).
DISCUSSION
The field of regenerative medicine is
quickly advancing. Therapeutic applica-
tions of hESC-derived oligodendrocyte
progenitor cells (www.geron.com) and
hESC-derived retinal pigment epithelial
cells (www.advancedcell.com) have
recently been initiated in patients with
acute spinal cord injury and Stargardt’s
macular dystrophy, respectively. MorePhase I clinical trials are expected within the next 5–10 years (Lo-
max et al., 2007). One issue critical to the realization of such
goals is the elimination of the immunologic barrier that presently
precludes the successful application of cell-based regenerative
therapy (Carpenter et al., 2009; Chidgey et al., 2008). The focus
of this study was to characterize the immunogenic properties of
ESCs, iPSCs, and their differentiated derivatives and to evaluate
the efficacy of blockade of leukocyte costimulatory molecules as
a way to induce transplanted cell engraftment and survival.
Future clinical applications of pluripotent cells for regenerative
therapy will probably involve allogeneic transplantation setting.
However, at the present time a comprehensive study of hESC
immunogenicity in humans is not yet feasible due to ethical
reasons and safety constrains. As a next best option, we
initially focused on the allogeneic transplantation scenario. We17, March 4, 2011 ª2011 Elsevier Inc. 315
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approach to induce engraftment of mESCs in a murine host.
However, conclusions drawn frommESCs possibly may not reli-
ably be extrapolated to hESCs. One major difference between
the two cell populations is that in the undifferentiated state
mESCs express undetectably low levels of MHC-I (H2-Kb)
(Abdullah et al., 2007; Bonde and Zavazava, 2006), whereas
hESCs demonstrate low but detectable levels of MHC-I expres-
sion. Similarly, differentiation of hESCs induces increased
MHC-I expression. For these reasons, it was important to also
demonstrate the immunosuppressive efficacy of costimulatory
blockade to prevent the rejection of undifferentiated hESCs as
well as spontaneously differentiated hESCs and in vitro differen-
tiated hESC-ECs and miPSC-NSCs.
Both undifferentiated and spontaneously differentiated hESCs
were rejected in the absence of immunosuppression and
demonstrated stable engraftment at all time points assayed in
the presence of costimulatory blockade treatment. In the
absence of immunosuppression, hESC-ECs were rejected by
day 7, whereas treatment with costimulatory blockade permitted
hESC-EC survival similar to NOD/SCIDmice. Overall, costimula-
tory blockade is more advantageous than more common forms
of immunosuppression (e.g., tacrolimus, sirolimus) because it
involves only a brief period of administration, produces minimal
systemic toxicity, and induces superior long-term engraftment
of murine and human pluripotent cells.
As an alternative approach to circumvent cellular rejection
following transplantation, the use of hiPSCs has been suggested
because they can be derived from the recipient and thusmay not
provoke an immune response (Byrne, 2008). However, it may not
be economically feasible to offer this type of treatment to the
population at large, nor logistically feasible to safely develop
autologous hiPSCs for transplantation in patients with acute
injury such as spinal cord trauma, stroke, or myocardial infarc-
tion. In the future, it is possible that allogeneic hiPSC transplan-
tation would be necessary in certain scenarios, which therefore
would necessitate the development of immunotolerance strate-
gies. At present, the immunogenic properties of hiPSCs remain
largely unknown, as no data exist regarding the immune
response toward hiPSCs. The only prior study to investigate
the immune properties of iPSCs focused on miPSCs and their
susceptibility to NK-cell-mediated immune rejection (Dressel
et al., 2010). This study investigates the immunogenic properties
of hiPSCs. We demonstrate that xenogeneic hiPSCs are
rejected under similar kinetics as hESCs and that immunosup-
pression with costimulatory blockade successfully mitigates
this immune rejection. Similarly, allogeneic transplantation of
undifferentiated miPSCs or differentiated miPSC-NSCs results
in immune rejection by 21 days after transplantation, whereas
engraftment in animals treated with costimulatory blockade
was similar to NOD/SCID mice. This is important because if
future clinical applications of iPSC-based therapies involve an
allogeneic transplantation setting, costimulatory blockade may
be a viable immunosuppressive approach to mitigate the alloge-
neic immune response.
In summary, this study demonstrates that a short course of
costimulatory blockade treatment is sufficient to induce engraft-
ment of allogeneic mESCs and miPSCs as well as xenogeneic
hESCs, hiPSCs, and their differentiated derivates. Our data316 Cell Stem Cell 8, 309–317, March 4, 2011 ª2011 Elsevier Inc.suggest that costimulatory blockade permits transplanted cell
engraftment by decreasing the expression of proinflammatory
cytokines (e.g., IL-2, Tnfrsf9), decreasing the polarization of
naive T cells toward a type I phenotype, increasing the establish-
ment of a proapoptotic phenotype, and inducing clonal anergy.
Further demonstrations of successful management of transplant
rejection as shown here will help realize the full potential of stem
cell-based regenerative therapies in the future.
EXPERIMENTAL PROCEDURES
Transduction, Transplantation, and In Vivo Tracking
of Pluripotent Cells
Formation of miPSCs and hiPSCs was performed as previously described
(Kim et al., 2009; Sun et al., 2009). H7 hESCs (Wicell), mouse ES-D3 cells
(ATCC), miPSCs, and hiPSCs were transduced with a Fluc-eGFP double-
fusion construct by lentivirus-based techniques as previously described
(Cao et al., 2008). Differentiation of hESCs into hESC-ECs and miPSCs into
miPSC-NSCs was performed as previously described (Li et al., 2009; Naka
et al., 2008). For cell transplantation experiments, 1 3 106 human-derived
and 53 105 mouse-derived cells were injected into the gastrocnemius muscle
of recipient mice. Transplanted cell survival was longitudinally monitored via
BLI by using the Xenogen In Vivo Imaging System (Caliper Life Sciences).
Briefly, D-Luciferin (Promega) was administered intraperitoneally at a dose
of 375 mg/kg of body weight. Animals were placed in a light-tight chamber,
and photons emitted from luciferase-expressing cells were collected with inte-
gration times of 5 s to 2min, depending on the intensity of the bioluminescence
emission. BLI signal was quantified inmaximumphotons per second per centi-
meter square per steradian (p/s/cm2/sr) and presented as log10[photons per
second]. For immunosuppressive therapy protocol, female BALB/c mice
(8–10 weeks old) were randomized to receive TAC (Sigma- Aldrich), SIR
(Rapamune oral solution; Sigma- Aldrich), anti-CD40L (MR-1), anti-LFA-1
(M17/4), or CTLA4-Ig (BioXCell). TAC and SIR were administered once daily
by oral gavage, 4 mg/kg/d for TAC and 3 mg/kg/d for SIR. Anti-CD40L, anti-
LFA-1, and CTLA4-Ig were administered at a dose of 20 mg/kg on days 0, 2,
4, and 6 after transplantation. For statistical analysis, comparisons between
groups were done by independent sample t tests or analysis of variance
(ANOVA) with Fisher’s least significant difference (LSD) post hoc or Bonferroni
post-tests, where appropriate. Differences were considered significant for
p < 0.05. All procedures performed were approved by the Animal Care and
Use Committee of Stanford University. For microarray data analysis and func-
tional annotation, the RNA samples were hybridized to the Affymetrix Mouse
430_2 chips. Data sets were analyzed with GeneSpring GX 10.0 software as
detailed in the Supplemental Experimental Procedures. Data normalization
was followed by Student’s t test (p value < 0.05; fold change cut off of 2.0)
and hierarchical clustering to obtain the significantly expressed genes. Their
functional annotation was carried out with Ingenuity IPA pathway analysis
software.
More detailed protocol information is available in the Supplemental Experi-
mental Procedures.
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